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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, relapsing-
remitting autoimmune disease which primarily affects the skin, 
joints, and kidneys but may involve any organ system, including 
peripheral, autonomic, or central nervous system (CNS).1 The 
CNS involvement may be considered primary if directly related 
to SLE activity or secondary when related to treatment compli-
cations, infections, or metabolic abnormalities such as uremia.2 
The neuropsychiatric involvement in SLE (NPSLE), first men-
tioned by Kaposi more than 100 years ago, remains one of the 
main challenges facing the rheumatologist and other physicians.2 
NPSLE can precede the onset of lupus or occur at any time 
during its course, most frequently within the first three years.3-6 
The prevalence of CNS involvement in SLE ranges from 14% 
to 80%, depending on the diagnostic criteria.7 SLE commonly 
involves the meninges, cranial nerves, cerebrum, spinal cord, 
and rarely involves the hindbrain, causing rhombencephali-
tis (RE), which is a syndrome of multiple causes and variable 
outcomes. The term “rhombencephalitis” refers to an inflam-
matory disease of the rhombencephalon or the hindbrain, 
which is composed of the pons, cerebellum, and the medulla 
oblongata. The term is derived from the Greek word, “rhom-
bos” meaning a lozenge-shaped figure, plus “enkephalos”, 
meaning the brain.8-10 No cases of SLE and rhombencepha-
litis were identified in a search of the medical literature.
CASE REPORT
The patient was a 43-year-old, right-handed, Caucasian 
female who presented to a local hospital several days af-
ter returning from a trip to Mexico. Her complaints included 
nausea, vomiting, urinary retention, headaches, and neck 
stiffness. The symptoms began suddenly while she was in 
Mexico, though she was not seen by a healthcare provider un-
til she returned home. Her past medical history revealed she 
takes cetirizine as needed for seasonal allergies. She lived on a 
farm with her husband and two children. She denied any to-
bacco, alcohol, or illicit drug use. She had a family history of 
colon cancer; otherwise, family history was noncontributory.
She was admitted to the hospital at time of presentation and 
diagnosed with bacterial meningitis. She was treated empiri-
cally with vancomycin, ceftriaxone, and dexamethasone. She 
showed complete improvement clinically and was discharged 
home with a steroid taper and a total of 21 days of ceftriaxone.
The patient responded well until six months later when she 
again developed nausea, vomiting, diarrhea, and urinary reten-
tion. She was admitted to the same hospital for work-up. Mag-
netic resonance imaging (MRI) of the brain revealed a T2 hyper-
intensity at C2 - C3. A lumbar puncture revealed a red blood 
count of 2 UL, a white blood count of 63 UL with 31% neutro-
phils and 30% lymphocytes, glucose of 42 mg/dl, and protein of 
41 mg/dl. Gram stain and culture on cerebrospinal fluid were 
negative. Other infectious studies also were negative, including 
West Nile, varicella zoster, and human immunodeficiency virus.
Rheumatologic serologic evaluation consisted of a positive 
antinuclear antibody test with titer 1:160 and positive anti-ds 
DNA. All other studies were negative, including rheumatoid 
factor, anti-Smith, anti-RNP, anti SSA/SSB, c-ANCA, and p-
ANCA. The antiphospholipid antibodies were negative. Neu-
roinflammatory work-up revealed a negative neuromyelitis op-
tica antibody, no oligoclonal bands on cerebrospinal fluid, and 
normal methylmalonic acid and serum protein electrophoresis.
The patient was diagnosed with transverse myeli-
tis at the outside facility without having clear findings on 
MRI to support that diagnosis, which was based solely on 
symptoms of urinary retention. She was started on meth-
ylprednisolone, 1 gram for three days. Urinary reten-
tion resolved, but the patient remained fatigued. Steroids 
were discontinued and the patient was discharged home.
No acute events occurred until eight weeks later when she again 
presented to her local hospital with nausea, vomiting, diarrhea, 
urinary retention, and fevers. Her temperature prior to presen-
tation was 39.5°C. Transverse myelitis was suspected again and 
the patient was transferred to our facility for further evaluation.
Upon presentation to our facility, the patient’s exam was 
non-focal and unremarkable except erythematous rash on chest 
and back. She was alert and oriented to person, place, and 
time. Speech was intact for fluency, comprehension, articula-
tion, repetition, and naming. Cranial nerves II-XII were intact.
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Strength was 5/5 throughout; deep tendon reflexes were 2/4 
throughout, and plantar response was down-going. Coordina-
tion was intact to finger-to-nose, heel-to-shin, and rapid alter-
nating movements. Sensation was intact to light touch and pin 
prick; vibratory sensation was felt for more than 10 seconds at 
the bilateral great toes. Muscle tone and bulk were normal with 
no fasciculation, tremor, or pronator drift. Gait was normal and 
the patient was able to perform heel, toe, and tandem walk.
MRIs of the head and cervical spine revealed a fluid-at-
tenuated inversion recovery (FLAIR) signal abnormality in 
the dorsal medulla and left lateral upper cervical spinal cord. 
This finding was not present on films performed at the out-
side facility. There was no MRI or clinical finding suggestive 
of transverse myelitis. Lumbar puncture revealed an open-
ing pressure of 20 cm H2O, red blood cell count of 30/UL, 
white blood cell count of 80/UL with 6% neutrophils and 56% 
lymphocytes, glucose of 35 mg/dl, and protein of 48 mg/dl. 
Clinically, the patient did not have signs of infection. 
Her fever had resolved. An infectious disease specialist was 
consulted and agreed with holding antibiotics at that time. 
Fever returned with nightly spikes to greater than 103°F. 
She was treated with acetaminophen and fever resolved 
with one dose. The patient required frequent catheteriza-
tion to empty her bladder. All other symptoms persisted.
Lumbar puncture was repeated two days after admis-
sion and revealed opening pressure of 8 cm H2O, red blood 
cell count of 0, white blood cell count of 380 with 63% neutro-
phils and 20% lymphocytes, glucose of 32 mg/dl, and protein 
of 69 mg/dl. Oligoclonal bands were negative. In light of this 
increase in white blood cell count, MRI findings in the brain-
stem, and return of fever, the patient was started empirically 
on ampicillin for Listeria coverage as it was suspected as the 
most likely organism contributing to her rhombencephalitis. 
Her fevers continued cyclically with spikes of greater 
than 102°F overnight every night. Rheumatologic work-
up revealed antinuclear antibodies of 380 with nucleolar 
pattern, complement C3 of 19.6 mg/dl, complement C4 of 
greater than 5.0 mg/dl, complement CH50 of 3 AU, anti-
Smith positive, anti-RNP positive, anti-SSA and SSB nega-
tive, and ds-DNA positive. IgM, IgA, and IgG were with-
in normal limits. Histoplasma antigen also was negative. 
The patient had an erythematous rash on her back and 
chest throughout admission. The patient reported a similar 
rash had accompanied her two prior episodes as well, which 
would improve once steroids were initiated. The rash was de-
scribed as a v-shaped, photo-distributed erythematous area 
with scaly papules on the anterior chest (Figure 1). A punch 
biopsy was consistent with cutaneous lupus erythematosus 
(Figure 2). The v-shape rash and interface dermatitis can be 
seen in dermatomyositis, but the patient had no muscle weak-
ness, Gottron’s papules, and heliotrope rash on physical ex-
amination and her CPK, aldolase and anti Jo were negative.
Figure 1. A v-shaped, photo-distributed erythematous area with scaly 
papules on the anterior chest. 
Figure 2. Vacuolar interface dermatitis with scale, epidermal thinning 
and scattered necrotic keratinocytes in the epidermal spinous layer; 
basal layer vacuolization and a dermal infiltrate of lymphocytes, histio-
cytes and melanophages (hematoxylin-eosin, X200). 
Lumbar puncture was repeated and revealed an opening 
pressure of 12.5 cm H2O, red blood cell count of 53/UL, white 
blood cell count of 100/UL with 19% neutrophils and 57% lym-
phocytes, glucose of 55 mg/dl, and protein of 176 mg/dl. Ampicil-
lin was discontinued in light of these results as well as no appre-
ciable improvement in cerebrospinal fluid white blood cell count 
after one week of treatment. The patient was started on predni-
sone for systemic lupus erythematosus and discharged home.
Since discharge, the patient has been followed closely as 
an outpatient. Disease modifying anti-rheumatic drug thera-
py (DMARD) was initiated with mycophenolate mofetil 1,000 
mg twice a day and hydroxychloroquine 200 mg twice a day. 
She improved clinically and has been tapered off prednisone.
DISCUSSION
Rhombencephalitis (RE) has a wide variety of etiolo-
gies, some potentially severe and life threatening with-
out proper early diagnosis and treatment. The etiologies 
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include infections, autoimmune diseases, and paraneoplastic 
syndromes.2 The most common infectious etiologies include 
Listeria, enterovirus 71, and herpes viruses, while the most 
common autoimmune etiology is Behçet’s disease. RE is seen 
in SLE and relapsing polychondritis.11-13 The exact pathogen-
esis is not known, but large numbers of pathophysiologic pro-
cesses are hypothesized to be involved, including anti-neuronal 
antibodies, antibodies against ribosomal P-protein, cytokines, 
vascular injury induced by circulating immune complex, oc-
clusive vasculopathy as a result of endothelial cell activation 
induced by cytokines and complement activation, or macro- 
and microvascular thrombosis induced by antiphospholipid 
antibodies. In the later stages of disease, cerebrovascular mani-
festations often are related to accelerated atherosclerosis.1,14,15 
However, direct and unequivocal evidence for the implica-
tion of any of the above-mentioned mechanisms is lacking.
 The clinical features of RE include altered mental status, hal-
lucination, headache, unilateral cranial nerve paresis (mainly 
V, VII, VI, IX, and X), cerebellar deficits (hemiataxia, vertigo, or 
dysarthria), respiratory failure, dysphagia, quadriplegia, ocular 
movement dysfunction, meningitis, and encephalopathy.16-18 
Our patient had headache followed by the development of en-
cephalopathy. There is no single test laboratory or imaging find-
ing which is diagnostic for NPSLE. The diagnosis is established 
based on the constellation of clinical presentation, serologic tests, 
and neuroimaging techniques which are used to exclude other 
potential etiologies prior to the diagnosis of SLE related RE. 
 Our patient did not have another possible explanation for 
RE and her serologic testing was supportive of a new diag-
nosis of SLE (SLICC classification criteria: cutaneous lupus, 
positive ANA, positive anti-ds DNA, and hypocomplement-
emia). The serologic studies revealed elevated anti-double 
stranded DNA and hypocomplementemia, suggestive of active 
disease. The cerebrospinal fluid analysis in CNS lupus usu-
ally presents with lymphocytic pleocytosis and elevated pro-
tein.19 MRI of the brain is the imaging modality of choice in 
case of CNS lupus, especially rhombencephalitis. The usual 
MRI findings in rhombencephalitis are increased signal inten-
sity in the pons, medulla, upper cervical cord, and cerebellum 
more frequently than the midbrain on T2-weighted images.20
 Therapy usually consists of high-dose intravenous corti-
costeroids followed by slow oral tapering doses.21,22 The most 
commonly used steroid sparing agents in these cases are aza-
thioprine or cyclophosphamide. Less frequently used im-
munosuppressive agents include cyclosporine, methotrexate, 
and anti–tumor necrosis factor alpha (TNF-α) agents.20-23 The 
most commonly used steroid sparing agents are azathioprine, 
mycophenolate mofetil, or cyclophosphamide. Mycophe-
nolate mofetil was chosen given its more favorable side ef-
fect profile compared to cyclophosphamide and case reports 
of aseptic meningitis in association with azathioprine.23-26
 Some poor prognostic factors include repeated attacks, in-
complete recovery, progression of disease, and a high level 
of CSF pleocytosis during the acute attack.24,26 About 25% 
of patients have complete recovery, while 75% have re-
sidual motor, sensory, visual, and cognitive impairments.
CONCLUSION
 SLE may have variable CNS manifestations. SLE should be con-
sidered as a potential cause of rhombencephalitis. MRI is useful in 
demonstrating brain lesions and in evaluating treatment efficacy.
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